Investors’ ESG Expectations for Drug Developers

With more than $500 billion flowing into ESG-focused funds over the past year, this fastest growing asset management class is rewriting expectations for biopharma companies seeking to attract and retain investment. This panel will explain the emerging risks and opportunities created by ESG funds that will increasingly impact drug developers' strategic planning.